The RxPrep Course Book is published annually. Information in the Course Book and Test Banks is up to date at the time of publishing, but drug information can change rapidly. Refer to the Updates on this page for NAPLEX-relevant information that becomes available before the next RxPrep Course Book is published. Guideline updates that may be relevant to NAPLEX are included. If we find anything that needs a correction or clarification in the RxPrep Course Book, it will be included in the Errata table on this page.
| Page | Update Type | Description | ||||||
|---|---|---|---|---|---|---|---|---|
| Chapter 1: Preparing for NAPLEX with RxPrep | ||||||||
| p. 12 | Revised NABP NAPLEX Competency Statements Effective January 1, 2021 | NABP has released revised NAPLEX Competency Statements (their blueprint of tested items). Impact for NAPLEX Candidates testing after January 1, 2021:
Comparison of 2020 and 2021 NAPLEX Competency Areas:
Individual Competency Statement wording is different, and often more descriptive and detailed, but the items that will be tested are the same:
| ||||||
| Chapter 41: Asthma and Chapter 42: Chronic Obstructive Pulmonary Disease | ||||||||
| p. 598, 612 & 613 | New Drug Approval | A new three-drug combination inhaler, budesonide/formoterol/glycopyrrolate (Breztri Aerosphere), has been approved for COPD. | ||||||
| p. 598 | Labeling Change | Umeclidinium/vilanterol/fluticasone (Trelegy Ellipta) has been FDA-approved for maintenance treatment of asthma in patients ≥ 18 years old. | ||||||
| Chapter 44: Diabetes | ||||||||
| p. 633 | Labeling Change | Dapagliflozin (Farxiga) has been FDA-approved to reduce the risk of cardiovascular death and hospitalization in heart failure with reduced ejection fraction without diabetes. | ||||||
| Chapter 53: Acute & Critical Care Medicine and Chapter 58: Pain | ||||||||
| p. 735 & 778 | New Drug Approval | Oliceridine (Olinvyk) is a new IV opioid agonist approved for moderate to severe acute pain in adults. It is indicated for short-term use in controlled clinical settings (i.e., inpatient or outpatient procedures). | ||||||
| Page | Description |
|---|---|
| Chapter 15: Compounding I | |
| p. 247 | The section on "Media-Fill Test" should include this statement: "Media-fill testing must be performed initially during training and at least annually for low- and medium-risk level compounding and semiannually for high-risk compounding." |
| p. 250 | On the clipboard describing USP 797 cleaning requirements, the minimum frequency of cleaning the walls, windows, shelving, bins, carts, chairs and ceiling should be monthly. |
| Chapter 23: Infectious Diseases II | |
| p. 389 | In the Study Tip Gal for HAP/VAP: Selecting an Empiric Regimen, the section on “Antibiotics for Pseudomonas (do not use two beta-lactams together)” should include aztreonam. |
| Chapter 26: Human Immunodeficiency Virus | |
| p. 433 | In the row for Descovy, cross out the statement in the right column. |
| p. 436 | The answer key for the fill-in-the-blank quiz should say:
|
| Chapter 44: Diabetes | |
| p. 629 | The last bullet under Vaccinations should say "Pneumococcal vaccine: Pneumovax 23 (1 dose before age 65)." |
| p. 639 | In the Study Tip Gal for Converting Between Insulins, Exception #1 should say "NPH dosed BID → Lantus, Basaglar or Toujeo dosed daily." |
View 2020 RxPrep Course Book Guideline/Drug Updates and Errata
Take your studies with you wherever you go.
Create an account to explore the features of our site, sample our products and take our two FREE Assessment Tests.